Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cystemustine INSERM.

B Palmer1

  • 1Auckland University, Cancer Research Laboratory, School of Medicine, Private Bag 92019, Auckland, New Zealand. b.palmer@auckland.ac.nz

Idrugs : the Investigational Drugs Journal
|May 10, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NWChem: Past, present, and future.

The Journal of chemical physics·2020
Same author

An investigation of the effects of procalcitonin testing on antimicrobial prescribing in respiratory tract infections in an Irish university hospital setting: a feasibility study.

The Journal of antimicrobial chemotherapy·2019
Same author

Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003-2015: A national cohort study.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Preliminary report: Surgical outcomes following genitoplasty in children with moderate to severe genital atypia.

Journal of pediatric urology·2018
Same author

Prospective assessment of cosmesis before and after genital surgery.

Journal of pediatric urology·2016
Same author

CEVL training to SFU grade pediatric hydronephrosis: a guide for pediatric caregivers.

Journal of pediatric urology·2015
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Cystemustine, an anticancer drug, shows potential against various cancers. Its toxicity in mice is linked to circadian rhythms in O6-alkylguanine-DNA alkyltransferase (AGT) activity, suggesting chronotherapy benefits.

Area of Science:

  • Oncology
  • Pharmacology
  • Chronobiology

Background:

  • Cystemustine is a novel chloroethyl-nitrosourea developed as an anticancer agent.
  • It is currently undergoing Phase II clinical trials for several advanced cancers, including melanoma, head and neck, renal, and colorectal cancers.
  • Preliminary data suggests moderate activity against malignant gliomas as a second-line treatment.

Purpose of the Study:

  • To investigate the chronopharmacology of cystemustine, focusing on the influence of circadian dosing time on its toxicity.
  • To explore the relationship between cystemustine's antitumor activity and the circadian rhythm of O6-alkylguanine-DNA alkyltransferase (AGT) in mice.

Main Methods:

  • A study involving 368 synchronized male B6D21F1 mice to assess the impact of circadian dosing on cystemustine toxicity, with leukopenia as a primary endpoint.

Related Experiment Videos

  • Analysis of O6-alkylguanine-DNA alkyltransferase (AGT) activity in the liver of 31 mice at six different circadian times.

    • Main Results:

    • Cystemustine exhibits potent antitumor activity in mice and has a short plasma half-life, suggesting potential for circadian scheduling.
    • A significant circadian rhythm was observed in both cystemustine toxicity and liver AGT activity in mice.
    • Leukopenia was identified as the main hematological toxicity associated with cystemustine treatment.

    Conclusions:

    • Circadian rhythms significantly influence cystemustine toxicity and its efficacy.
    • The observed rhythm in liver AGT activity is a key mechanism underlying the chronopharmacology of cystemustine.
    • These findings support the potential for optimizing cystemustine treatment through circadian-timed administration to enhance tolerability and dose intensity.